These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 11917244)

  • 1. Impact of highly active antiretroviral therapy on individual AIDS-defining illness incidence and survival in Australia.
    Dore GJ; Li Y; McDonald A; Ree H; Kaldor JM;
    J Acquir Immune Defic Syndr; 2002 Apr; 29(4):388-95. PubMed ID: 11917244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy.
    Dore GJ; Correll PK; Li Y; Kaldor JM; Cooper DA; Brew BJ
    AIDS; 1999 Jul; 13(10):1249-53. PubMed ID: 10416530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
    Ives NJ; Gazzard BG; Easterbrook PJ
    J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AIDS-defining illnesses: a comparison between before and after commencement of highly active antiretroviral therapy (HAART).
    Lian YL; Heng BS; Nissapatorn V; Lee C
    Curr HIV Res; 2007 Sep; 5(5):484-9. PubMed ID: 17896968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opportunistic infections and other AIDS-defining illnesses in Poland in 2000-2002.
    Podlasin RB; Wiercinska-Drapalo A; Olczak A; Beniowski M; Smiatacz T; Malolepsza E; Juszczyk J; Leszczyszyn-Pynka M; Mach T; Mian M; Knysz B; Horban A
    Infection; 2006 Aug; 34(4):196-200. PubMed ID: 16896577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy.
    Dore GJ; McDonald A; Li Y; Kaldor JM; Brew BJ;
    AIDS; 2003 Jul; 17(10):1539-45. PubMed ID: 12824792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features and predictors of survival of AIDS-related non-Hodgkin's lymphoma in a population-based case series in Sydney, Australia.
    Robotin MC; Law MG; Milliken S; Goldstein D; Garsia RJ; Dolan GM; Kaldor JM; Grulich AE
    HIV Med; 2004 Sep; 5(5):377-84. PubMed ID: 15369514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential impact of combined antiretroviral therapy on the survival of italian patients with specific AIDS-defining illnesses.
    Conti S; Masocco M; Pezzotti P; Toccaceli V; Vichi M; Boros S; Urciuoli R; Valdarchi C; Rezza G
    J Acquir Immune Defic Syndr; 2000 Dec; 25(5):451-8. PubMed ID: 11141245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of AIDS-Defining Opportunistic Infections and Mortality during Antiretroviral Therapy in a Cohort of Adult HIV-Infected Individuals in Hanoi, 2007-2014.
    Tanuma J; Lee KH; Haneuse S; Matsumoto S; Nguyen DT; Nguyen DT; Do CD; Pham TT; Nguyen KV; Oka S
    PLoS One; 2016; 11(3):e0150781. PubMed ID: 26939050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and prognosis of CMV disease in HIV-infected patients before and after introduction of combination antiretroviral therapy.
    Salzberger B; Hartmann P; Hanses F; Uyanik B; Cornely OA; Wöhrmann A; Fätkenheuer G
    Infection; 2005 Oct; 33(5-6):345-9. PubMed ID: 16258865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary manifestations of HIV infection in the era of highly active antiretroviral therapy.
    Wolff AJ; O'Donnell AE
    Chest; 2001 Dec; 120(6):1888-93. PubMed ID: 11742918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changing trends in clinical AIDS presentations and survival among HIV-1-infected women.
    Charurat M; Blattner W; Hershow R; Buck A; Zorrilla CD; Watts DH; Paul M; Landesman S; Adeniyi-Jones S; Tuomala R;
    J Womens Health (Larchmt); 2004; 13(6):719-30. PubMed ID: 15333287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of chronic hepatitis C infection to rates of AIDS-defining illnesses in a Canadian cohort of HIV seropositive individuals receiving highly active antiretroviral therapy.
    Raboud J; Anema A; Su D; Klein MB; Zakaryan A; Swan T; Palmer A; Hosein S; Loutfy MR; Machouf N; Montaner JS; Rourke SB; Tsoukas C; Hogg RS; Cooper C;
    HIV Clin Trials; 2012; 13(2):90-102. PubMed ID: 22510356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Declining incidence of AIDS-defining opportunistic illnesses: results from 16 years of population-based AIDS surveillance.
    Schwarcz L; Chen MJ; Vittinghoff E; Hsu L; Schwarcz S
    AIDS; 2013 Feb; 27(4):597-605. PubMed ID: 23079812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy.
    Grabar S; Lanoy E; Allavena C; Mary-Krause M; Bentata M; Fischer P; Mahamat A; Rabaud C; Costagliola D;
    HIV Med; 2008 Apr; 9(4):246-56. PubMed ID: 18366449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential improvement in survival among patients with AIDS after the introduction of HAART.
    Couzigou C; Semaille C; Le Strat Y; Pinget R; Pillonel J; Lot F; Cazein F; Vittecoq D; Desenclos JC;
    AIDS Care; 2007 Apr; 19(4):523-31. PubMed ID: 17453593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival.
    Diamond C; Taylor TH; Aboumrad T; Anton-Culver H
    Cancer; 2006 Jan; 106(1):128-35. PubMed ID: 16329140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997.
    Jones JL; Hanson DL; Dworkin MS; Alderton DL; Fleming PL; Kaplan JE; Ward J
    MMWR CDC Surveill Summ; 1999 Apr; 48(2):1-22. PubMed ID: 12412613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in reported AIDS defining illnesses (ADIs) among participants in a universal antiretroviral therapy program: an observational study.
    Jafari S; Chan K; Aboulhosn K; Yip B; Lima VD; Hogg RS; Montaner J; Moore DM
    AIDS Res Ther; 2011 Sep; 8():31. PubMed ID: 21892955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pneumocystis jiroveci pneumonia in patients with AIDS in the inner city: a persistent and deadly opportunistic infection.
    Tellez I; Barragán M; Franco-Paredes C; Petraro P; Nelson K; Del Rio C
    Am J Med Sci; 2008 Mar; 335(3):192-7. PubMed ID: 18344692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.